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Available online 27 October 2016Background: Clopidogrel, a prodrug is found to be less effective in inhibiting the platelet aggregation when ad-
ministered along with PPI's in patients undergoing cardiac stent, ST segment elevated Myocardial infarction
(STEMI) followed by percutaneous coronary intervention (PCI). Clopidogrel binds to CYP2C19, a hepatic enzyme
to get converted to its active metabolite in order to achieve desired pharmacological activity. The cytochrome
P450 3A4which is partially involved in themetabolism of clopidogrel alsometabolizes statins,mainly atorvastat-
in to the greater extent.
Methodology: In the current study patients on PPI'swith dual antiplatelet therapy and patients on PPI's and statins
with dual antiplatelet therapy are considered to understand the potential drug–drug interactions (pDDI) among
the South Asian population. Platelet aggregation was measured in 61 patients undergoing coronary artery stent
implantation treated with clopidogrel and aspirin along with PPI's and statins.
Results: It was observed that omeprazole and atorvastatin, but not pantoprazole and rosuvastatin, inhibited the
antiplatelet activity of clopidogrel. The percent platelet aggregation was 72 ± 6 (p = 0.001) and 43 ± 23
(p = 0.027) in the presence of clopidogrel with omeprazole and pantoprazole respectively. Aggregation was
found to be 91 ± 4 (p = 0.001) and 12 ± 23 (p = 0.031) in the presence of clopidogrel with atorvastatin and
rosuvastatin respectively.
Conclusion: A prominent drug–drug interaction was observed with patients on dual antiplatelet therapy along
with omeprazole and atorvastatin.
© 2016 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Potential drug−drug interaction1. Introduction
Clinical studies have indicated a potential drug–drug interaction
(pDDI) between dual antiplatelets (clopidogrel and aspirin) and clini-
cally prescribed PPI's like omeprazole, pantoprazole, esomeprazole [1]
and statins such as atorvastatin and rosuvastatin. Health care in tertiary
system consider drug–drug interactions as themajor concern due to the
alarmingmortality rate associated with these interactions. The compet-
itive binding of several classes of drugs to a singlemetabolic enzyme, cy-
tochrome P450which aremost likely to be present in the liver and other
hepatic tissues, leading to drug–drug interaction. These cytochrome
P450 enzymes alter the pharmacology of one drug due to competitive
binding of the other drug [2], thus leading to major pharmacokinetic
interaction..
is an open access article under the CDrug–drug interactions have become an important issue in health
care. It is now realized that many drug–drug interactions can be ex-
plained by alterations in the metabolic enzymes that are present in
the liver and other extra-hepatic tissues. Many of the major pharmaco-
kinetic interactions between drugs are due to hepatic cytochrome P450
(P450 or CYP) enzymes being affected by previous administration of
other drugs. After coadministration, some drugs act as potent enzyme
inducers, whereas others are inhibitors. However, reports of enzyme in-
hibition are very much more common. Understanding these mecha-
nisms of enzyme inhibition or induction is extremely important in
order to give appropriate multiple-drug therapies. In the future, it may
help to identify individuals at greatest risk of drug interactions and ad-
verse events [2].
Clopidogrel belongs to a thienopyridine class of drugs which inhibits
platelet aggregation in the patients undergoing percutaneous coronary
intervention and also reduces coronary stent thrombosis andmyocardi-
al infarction [3–5]. Clopidogrel converts to its active metabolite byC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and exhibits antiplatelet effect [6–9]. In animals, especially rats it's
found that cytochrome P450 1A2 is responsible for the activation of
clopidogrel [7], whereas in humans the activation of clopidogrel is
mostly by the cytochrome P450 2C19 and partly by 3A4 [9].
Patients receiving antiplatelet therapy are most commonly pre-
scribed with PPI's to reduce the gastrointestinal bleeding [10]. Cardio-
vascular events, stroke, myocardial infarction and mortality continue
to occur in patients with vascular diseases because of competitive bind-
ing of the ADP receptor blocker clopidogrel and PPI's to the isoenzymes
2C19 [11,12]. Patients with acute coronary syndrome are most likely to
have elevated levels of cholesterol which makes it necessary for statin
therapy. Thus evaluation of each drug concentration in a poly prescrip-
tion becomes atmost important.
The American College of Cardiology/American Heart Association
2007 Unstable Angina/Non-ST-Segment Elevation Myocardial Infarc-
tion guidelines recommend concomitant PPI therapy with aspirin and
clopidogrel in patients with a history of gastrointestinal bleeding [13].
Consequently, the number of patients affected by a PPI–clopidogrel in-
teraction could be substantial. In fact, a combined total of 100 million
prescriptions are written for both PPIs and clopidogrel annually [14].
However, this does not include all omeprazole use since, at some
strengths, it is available over-the-counter. It has been hypothesized
that PPI use concurrently with clopidogrel will increase the risk of
major adverse cardiac events [15].
Different isoforms of cytochrome P450 (CYP) metabolized different
types of substrates (or drugs molecule) and make them soluble during
biotransformation. Therefore, fate of any drug molecule depends on
how they are treated or metabolized by CYP isoform. There is a need
to develop models for predicting substrate speciﬁcity of major isoforms
of P450, in order to understand whether a given drug will be metabo-
lized or not. In-silicomethod for predicting the metabolizing capability
of major isoforms (e.g. CYP 3A4, 2D6, 1A2, 2C9 and 2C19) has been ex-
plained [16].
2. Material and methodology
In the current study, patients with acute coronary syndrome and
other cardiovascular diseases followed by stent implantation and percu-
taneous coronary intervention,where prospectively evaluated for plate-
let aggregation studies. Patients with prescription of clopidogrel and
aspirin along with PPI's and statins were under consideration.
The institutional review board approved the protocol, and a written
informed consent was signed by the patient/patient care taker, before
commencing the study.
i. Study site: This studywas conducted in JSS College of Pharmacy and
Department of Cardiology, JSSMedical College andHospital, Mysore.
ii. Study design: This was a prospective bioanalytical study.
iii. Study period: The study was conducted over a period of 19months,
from the month of June 2014 to December 2015.
iv. Study subjects: The study subjects were enrolled into the study
based on the study criteria
v. Study criteria
a. Inclusion criteria
1. Male or female between the ages of 40 to 60 years, inclusive who are
admitted in the hospital (in-patients)
2. Females must have negative results for pregnancy tests performed:
at Screening on a urine specimen obtained within 2 weeks prior to
initial study drug administration.
3. Body Mass Index (BMI) is 19 to 26, inclusive. BMI is calculated as
weight in kg divided by the square of height measured in meters.4. A condition of MI, stroke, heart attack etc. with percutaneous coro-
nary intervention admitted in the cardiology/other department in
the hospital.
5. Patients receiving the above said medications
6. Must voluntarily sign and date each informed consent, prior to the
initiation of any screening or study-speciﬁc procedures.
b. Exclusion criteria
1. History of signiﬁcant sensitivity to any drug.
2. Requirement for any over-the-counter and/or prescription medica-
tion other than above mentioned, vitamins and/or herbal supple-
ments, on a regular basis.
3. Use of anymedications (other than OTC/prescription), vitamins and/
or herbal supplements, within the 1-week period prior to study drug
administration.
4. Recent (6-month) history of drug or alcohol abuse.
5. Use of known inhibitors (e.g., ketoconazole) or inducers
(e.g., carbamazepine) of cytochrome P450 3A (CYP3A) within
1 month prior to study drug administration.
vi. Investigation and study protocols
The institutional review board approved the study protocols and
written informed consentwas obtained fromeach subject before enroll-
ment. In the study, 61 patients undergoing successful elective coronary
artery stent implantation received an oral loading dose of 300 mg of
clopidogrel (PLAVIX™) followed by 75 mg/day for 28 days.
Subjects enrolled for the study had undergone primary percutane-
ous coronary intervention followed by stent implantation, a standard
diagnostic treatment. All patients were enrolled and studied prospec-
tively. All the subjects received 300 mg of aspirin (NUSPRIN™) on ad-
mission and 200 mg/day thereafter throughout the study period.
Platelet aggregation activity was tested in blood samples withdrawn
in the pathology laboratory 60 ± 5 min after administration of chew-
able aspirin (baseline).
Eight patients were on PPI's alone, among them ﬁvewere prescribed
with 40 mg of omeprazole (PRIOSEC™) twice daily and three were on
pantoprazole (PANTODAC™) 40 mg twice daily. Seventeen patients
were on dual antiplatelet therapy along with PPI's.
Out of eleven patients on statin therapy, six were taking 40 mg of
atorvastatin (AVAS™) a day, and ﬁve were taking either 40 mg (n
5) of rosuvastatin (CRESTOR™) once daily. Platelet aggregation was
measured before clopidogrel administration and 24 h later. Platelet ag-
gregation measurements were repeated in ten patients on clopidogrel
and aspirin alone and ﬁfteen patients on clopidogrel plus PPI's and
statins 24 days after successful stent implantation.
Subjects were divided into 5 quartiles depending on the patients
who were on prescribed medications. Platelet aggregation induced by
the ADP was measured at 24 h compared with the baseline at 0 h after
the administration of clopidogrel loading dose was measured. Percent-
age aggregation was presented were presented categorically in the 5
quartiles. Mantel–Haenszel [2] analysis was used to test the linear
trend. Patients of ﬁrst quartile were compared with second till ﬁfth
quartiles using a 2-tailed Fisher's test. Variables were presented as
mean ± SD.
Baseline demography and clinical characteristics of patients on dual
antiplatelet therapy, PPI's and statins individually and in combinations
are mentioned in Table 1.
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3.1. Preparation of Platelet rich plasma (PRP)
Platelet-rich plasma was prepared by centrifugation of 5 mol/L of
ADP and was measured with a dual channel aggregometer (model
440, Chronolog, Havertown, PA). Chart recordings were monitored
on a Kipp-Zone Chart Recorder (Fisher Scientiﬁc, Chicago, IL).
The whole blood collected from the patients was anticoagulated
with sodium citrate (sodium citrate/whole blood ratio, 1:10) and cen-
trifuged at 10,000 rpm for 10min at room temperature for preparation
of platelet rich plasma (PRP). The prepared PRP was incubated for
30min at 37 °C in capped tubes with 14C-serotonin. The cloudy yellow
supernatant containing the platelets was separated without disturbing
theWBC and RBC cell layers. Platelet-poor plasma (PPP) was prepared
by centrifuging the remaining sample at 10,000 rpm for 20min at room
temperature [23]. Platelet function testing was completed within 3 h
after blood collection. The PRP was adjusted to a platelet count of 200
to 350 × 103/μL (200–350 × 109/L) after addition of PPP. Clinical sam-
ples should be assayedwith similar platelet counts in the normal range.
Platelet counts less than 100 × 103/μL (100 × 109/L) are not optimal for
these functional tests.
3.2. Evaluation
Platelet aggregation was determined by measuring the change in
the optical density (i.e., light transmittance) of stirred PRP after addi-
tion of the aggregating agent to the aggregometer cuvette. Platelet ag-
gregation occurs only if the PRP in the aggregometer cuvette is stirred,
usually at the rate of 800 to 1200 rpm. A Teﬂon-coatedmagnetic stirrer
was used. The aggregometer was standardized by placing the patient's
PPP sample in one channel to represent 100% light transmittance and
the patient's PRP sample in another channel representing 0% transmit-
tance. The increase in light transmittance from 0% to 100% is reﬂected
on the chart recorder as the aggregometer tracing. Usually, the baseline
of the patient's PRPwas adjusted to be at the 10% chart deﬂection level,
and the patient's PPP baseline was adjusted to the 90% level on the
chart recorder. The light transmittance of the PRP relative to the PPP
blank was recorded automatically. When an aggregating agent is
added to the PRP, platelet aggregates form, and this event results in
an increase in the light transmittance, which is recorded and used as
an index of platelet aggregation.
3.3. Calculations of platelet aggregation
The percentage of aggregationwas determined as the percentage of
chart deﬂection between 10% and 90% at its highest average point of
deﬂection on the chart recorder as follows:
Percentage of Aggregation
¼ Highest Average Point of Deflection–20ð Þ=80 100
4. Statistical analysis
Platelet activity was expressed as a percentage of baseline value.
Each patient served as his or her own control, and changes in platelet
activity were evaluated with paired t-test.
5. Results
Of the 61 patients enrolled, 46 (75%) were male, mean age was
55 ± 19 years, and mean time from symptom onset to admission
was 2.8 ± 2 h.
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Platelet aggregation studies showed a decrease in the percentage ag-
gregation after 24 h in all the seven combination of patient plasma sam-
ples. The percentage aggregation is shown in Table 2.
(B) The dual antiplatelets activity of clopidogrel and aspirin at 0 h
(dotted columns) and at 24 h (line columns) in patients treated with
or without PPI's and statins in different combinations. (C) Platelet ag-
gregation at 0 h (dotted columns) and at 7 h (line columns) after
clopidogrel and aspirin administration in patients with or without
statins (40 mg).
5.2. Effect of dual antiplatelet therapy
On the day of study, ADP-induced percentage platelet aggregation of
plasma collected after 7± 0.5 h of clopidogrel loadingwere inhibited to
30% of baseline 0 h (P 0.001) in the ﬁrst quartile. Whereas platelet ag-
gregation were inhibited only to 77% in patients on dual antiplatelets
along with PPI's and statins. The effect of dual antiplatelet therapy was
hindered in presence of omeprazole and atorvastatin when compared
to pantoprazole and rosuvastatin.
5.3. Platelet aggregation effect
Subjects were divided into 5 quartiles and the ADP-induced platelet
aggregation after 24 hwas comparedwith that of 0 h baseline activity of
each patient. Patients in the ﬁrst quartile were not resistant to
clopidogrel (30 ± 6% of baseline platelet aggregation). Whereas not
much signiﬁcant reduction in platelet aggregation in patients in the sec-
ond quartile till fourth quartile (Table 2), to 72± 4%, 62± 3%, and 55±
9% of the respective baselines (P b 0.005 for all, Fig. 1a). Inhibition in
platelet aggregation decreased signiﬁcantly in the ﬁrst quartile (P for
trend 0.01). Patients on dual antiplatelet therapy with omeprazole and
atorvastatin showed no signiﬁcant reduction in the platelet aggregation,
77±8% to baseline 96±4% (P=ns). Platelet aggregation reduced con-
siderably to 70±2% to the baseline 0 h (P b 0.005) in patients with dual
antiplatelets, pantoprazole and rosuvastatin.
5.4. Clinical conclusion
The number of cigarette smokers decreased signiﬁcantly and gradu-
ally from the ﬁrst through ﬁfth quartile (Table 1), but otherwise no sig-
niﬁcant differences were found in the other baseline demographic,
clinical characteristics and angiographic ﬁndings (Table 1). Also it was
found that the other demographic parameters didn't differ, such as pre-
scribed medications during hospital stay and in discharge summary
(Table 1).
All the 61 patients in the investigation were monitored with a con-
tinuous clinical update. During the period four patients developed re-
current STEMI, one patient suffered from peripheral arterial occlusion,
requiring immediate surgery. Two patients were reported with stent
thrombosis followed by MI. Therefore, seven patients had repeatedTable 2
Platelet aggregation of patient plasma samples.
Sl. no. Drug No. of patients Percentage
aggregation (%)
0 h 24 h
1. CLP & ASP 10 96 30
2. CLP & ASP with OME 9 92 72
3. CLP & ASP with PAN 8 94 62
4. CLP & ASP with OME & ROS 4 90 55
5. CLP & ASP with OME & ATR 6 96 77
6. CLP & ASP with PAN & ATR 3 91 70
7. CLP & ASP with PAN & ROS 2 92 56
Note: Average % aggregation in each group in ±SD.cardiovascular events, ﬁve of which occurred during treatment and
two patients during the clinical follow-up. Among the seven patients,
four patients resistant to clopidogrel (fourth quartile) and three were
from the ﬁfth quartile. In variance, major bleeding occurred in one of
the patient from fourth quartile.
Patients were senior citizens with repeated cardiovascular events (P
0.008), and had a lower percentage reduction of platelet aggregation
which persisted upto 24 h (90 ± 16% versus 72 ± 7%, P 0.001, Fig. 1).
6. Discussion
The overall goal of drug-metabolizing CYP enzymes is the conver-
sion of lipophilic drugs into more hydrophilic compounds to facilitate
elimination by the kidney. This study showed that clopidogrel is less ef-
fective in inhibiting platelet aggregation when co administered with
omeprazole, a CYP2C19 inhibitor and atorvastatin, a CYP3A4 substrate.
In contrast, when clopidogrel was administered with pantoprazole
and rosuvastatin, a hydrophilic drug not metabolized by the CYP sys-
tem, platelet aggregation inhibition was not altered. Furthermore,
in vivo studies demonstrated that clopidogrel is converted to its active
form mainly by CYP2C19 and partly metabolized by CYP3A4, the most
prominently expressed CYP in the human liver. We conclude that
omeprazole and atorvastatin, at doses routinely administered to pa-
tients, inhibits CYP450 isoenzymes activity in a dose-dependent man-
ner, and thereby decreases the metabolic conversion of clopidogrel to
its pharmacologically active form.
Individual patient care is atmost necessary because of many drugs
competing to get metabolized by CYP3A4, making it very important to
understand the efﬁcacy of clopidogrel in presence of other medications.
Platelet function testing is absolutely necessary to identify the aspirin
resistant patients. Patients suffering from acute coronary syndromes
[4], ST segment elevated MI and those on percutaneous coronary inter-
vention; clopidogrel is prescribed for more than 3months. In such cases
determining potential drug–drug interactionwith clopidogrel and other
medications becomes extremely important.
Clopidogrel, after an oral dose of 75 mg, gets hydrolyzed from its
methyl ester to inactive carboxylic acid derivative, which represents al-
most 85% of component related to clopidogrel in plasma. Therefore only
remaining around 15% of the drugmoiety is available for metabolism to
its active form. Therefore the level of active clopidogrel is less than 10–
15 folds as that of inactive carboxylic acid form.
Atorvastatin, a hydroxy acid is not responsible for the inhibition of
CYP3A4, whereas its lactone form, which is more lipophilic in nature
than the acid form competitively, inhibits the clopidogrel metabolism
through CYP3A4. Atorvastatin acid has been responsible for 75% of
HMG-CoA reductase activity. Atorvastatin lactone binds majorly to
CYP3A4 than any other substrate and causes drug -drug interaction [19].
Since the rate of competitive inhibition depends on the concentra-
tion and relative afﬁnity between two substrates to the binding site of
CYP2C19 and CYP3A4. If present in equivalent concentration, omepra-
zole and atorvastatin are potent inhibitors of most of the substrates
[19]. Clopidogrel mainly depends upon CYP2C19 to get converted to
its active moiety, but partially binds to CYP3A4 for metabolism. Omep-
razole inhibits CYP2C19 whereas atorvastatin inhibits CYP3A4, thus re-
ducing the antiplatelet action of clopidogrel.
Atorvastatin binds CYP3A4 thirty times more tightly than any other
substrateswhich are found in lower concentration. Atorvastatin inhibits
the metabolism of clopidogrel because of a very low concentration of
clopidogrel that binds to CYP3A4 than atorvastatin itself.
Since clopidogrel is an ADP receptor antagonist, a device which
allows to measure platelet aggregation in which ADP is used to
enhance platelet aggregation was required. Common turbidimetric
aggregometers are dependent on analyst differences and also gives indi-
rect results due to citrated platelet rich plasma containing various blood
components. Another instrument which measures activated platelets
by thrombin activating peptide to agglomerate ﬁbrinogen beads [23],
Fig. 1. The in vivo effect of PPI's and statins on the dual antiplatelets activity of clopidogrel and aspirin. (A) Platelet aggregation at 0 h (dotted columns) and at 24 h (line columns) after
clopidogrel and aspirin administration in patients treated without or with PPIs (40 mg).
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sample quantity was used in this study [11].
Cytochrome P450 isoenzyme, mostly 2C19 and partly 3A4 are re-
sponsible to convert clopidogrel prodrug to its active form. CYP3A4 is
triggered mainly by polycyclic aromatic hydrocarbons which arepresent in cigarette smoke [13]. Lau et al. [25], explains about the vary-
ing clopidogrel response with the metabolism of cytochrome P450 en-
zyme. Various other factors like receptor signal pathway and ADP
receptor polymorphism also varies the platelet aggregation response
by clopidogrel.
40 J.B. Nagavi et al. / IJC Metabolic & Endocrine 13 (2016) 35–40In the current study, having a small sample size comparatively, pro-
vides an observatory but not conﬁrmatory proof to conclude that the
clopidogrel resistance is mainly because of the competitive binding to
the enzyme CYP2C19 and CYP3A4. Also increase in the loading dose of
clopidogrelmay signiﬁcantly reduce the percentage of recurrent cardio-
vascular cases. However resistance to clopidogrel was observed in
STEMI patients.
7. Conclusion
Omeprazole showed considerably more clopidogrel resistance after
eliminating the effects of interindividual variability in clopidogrel me-
tabolism, compared to other PPI's and HMG-CoA reductase enhancer
regimens.
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